Eli Lilly, one of the global leaders in pharmaceutical innovation, has shown commitment to sustainable practices and improving health outcomes worldwide. The company has made significant investments in climate action, including pledges to reduce its carbon emissions and achieve net-zero emissions by 2030. Eli Lilly’s ESG rating reflects its leadership in advancing medical research, particularly in diabetes and oncology treatments. However, the company faces criticism for high drug prices and ongoing concerns about access to healthcare. Additionally, some stakeholders argue that Eli Lilly’s governance practices require further improvement, particularly with regard to transparency and ethical decision-making. Despite these challenges, Eli Lilly’s ESG score remains strong due to its contributions to public health and environmental sustainability. For more detailed insights, refer to the latest Eli Lilly ESG report.